Demis Hassabis, CEO of Google DeepMind, has successfully raised significant funding for his startup Isomorphic Labs, which focuses on using AI to accelerate the development of novel drugs. Founded in 2021 as a spinout of Google DeepMind, Isomorphic Labs is at the forefront of AI-driven drug innovation. The recent Series B funding round was led by Thrive Capital, a firm recognized for its investments in leading AI initiatives like OpenAI.

Google: Google, a subsidiary of Alphabet Inc., is a global technology leader that develops innovative products in search, cloud computing, and artificial intelligence, particularly through its DeepMind lab which focuses on advanced AI research including reinforcement learning and scientific applications. In this news, a prominent AI figure associated with Google DeepMind has raised significant funding for Isomorphic Labs, a 2021 Google spinout targeting AI-powered drug discovery, with Alphabet participating as an investor. This highlights Google’s continued influence in steering AI towards transformative healthcare solutions.

AI Application: The startup leverages AI to speed up the creation of novel drugs, led by Google DeepMind’s CEO Demis Hassabis in related efforts.
Spinout Origin: Isomorphic Labs emerged from Google DeepMind in 2021 to specialize in AI-driven drug development.
Funding Leadership: Thrive Capital, known for backing OpenAI, led the recent series B round for Isomorphic Labs.